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Abstract
Purpose The objective was to obtain a standardized
evaluation of available prostate cancer-specific quality of
life instruments used in patients with early-stage disease.
Methods We carried out systematic literature reviews in
the PubMed database to identify manuscripts which con-
tained information regarding either the development pro-
cess or metric properties of prostate cancer-specific quality
of life instruments. Each instrument was evaluated by two
experts, independently, using the Evaluating Measures of
Patient-Reported Outcomes (EMPRO) tool. An overall and
seven attribute-specific EMPRO scores were calculated
(range 0–100, worst to best): measurement model, reli-
ability, validity, responsiveness, interpretability, burden
and alternative forms.
Results Eight instruments and 57 manuscripts (2–15 per
instrument) were identified. The Expanded Prostate Cancer
Index Composite (EPIC) was the best rated (overall EM-
PRO score 83.1 points). Good results were also obtained by
University of California Los Angeles-Prostate Cancer
Index (UCLA-PCI), Patient-Oriented Prostate Utility Scale
(PORPUS) and Prostate Cancer Quality of Life Instrument
(PC-QoL) with 77.3, 70.5 and 64.8 points, respectively.
These four instruments passed with distinction the validity
and responsiveness evaluation. Insufficient reliability
results were observed for UCLA-PCI and PORPUS.
Conclusions Current evidence supports the choice of
EPIC, PORPUS or PC-QoL. Attribute-specific EMPRO
results facilitate selecting the adequate instrument for every
purpose. For longitudinal studies or clinical trials, where
responsiveness is the priority, EPIC or PC-QoL should be
considered. We recommend the PORPUS for economic
evaluations because it allows cost-utility analysis, and
EPIC short versions to minimize administration burden.
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Introduction
Prostate cancer is currently the most frequent solid neo-
plasm and the third cause of death in European men [1].
The increased tumor detection is associated with the use of
the prostate-specific antigen testing, which changed the
epidemiology of this tumor, by moving diagnosis to
younger patients at earlier stages. Now, men have to live
longer with their disease and with the treatment’s side
effects, which are mainly urinary, sexual and bowel prob-
lems [2, 3]. Therefore, Patient-Reported Outcomes (PROs),
such as health-related quality of life (HRQL), have
achieved an important role in the evaluation of treatment
benefits and harms in these patients [4, 5]. The first prostate
cancer-specific HRQL instruments, such as the prostate
module of the European Organization for Research and
Treatment of Cancer (EORTC QLM-P14) [6] or the
Prostate Cancer-Specific Quality of Life Instrument
(PROSQOLI) [7], were designed mainly for patients in
advanced disease stages and present significant limitations
when used in patients with localized disease.
The need for tools capable of capturing all relevant
aspects in patients diagnosed at early stages of disease led
to the development of several prostate cancer-specific
instruments. A recent systematic review [8] identified
almost 30 symptom measures either designed or adapted
for prostate cancer patients. Several share a similar content
and applicability, which makes it a complicated task to
select the right instrument for a specific purpose and set-
ting, calling for the need to evaluate those measures con-
sidering their strengths and weaknesses. The right choice
depends on both the instrument’s characteristics and the
specific study requirements (mainly objectives and avail-
able resources). A comparative evaluation among instru-
ments would be of great value to facilitate this selection
task.
Several attempts have been made to systemize evalua-
tion criteria for PROs. The GraQol Index was the first
instrument that generated a global score [9]. Currently,
there are two other tools used for this purpose, the COn-
sensus-based Standards for the selection of health status
Measurement INstruments (COSMIN) [10], and the Eval-
uating Measures of Patient-Reported Outcomes (EMPRO)
[11]. While the COSMIN was developed as a checklist for
evaluating the methodological quality of each individual
study, the EMPRO was designed to assess the quality of the
PRO measure by taking into account all the available
studies. EMPRO considers both the methods applied in the
studies and the adequacy of the results.
The quality of a PRO measure was defined by the EM-
PRO developers as the ‘‘degree of confidence that all pos-
sible bias has been minimized and that the information
about the process which led to its development and
evaluation is clear and accessible’’ [11]. The EMPRO
combines 3 fundamental aspects: (1) well-described and
established attributes for assessment, (2) expert reviewers to
conduct the assessment, and (3) scores that allow a direct
comparison among outcome measures. It is based on an
exhaustive series of recommendations regarding the ideal
attributes of PRO measures [12]. The EMPRO is a valid and
reliable tool that has proven its usefulness in comparing the
performance of generic [11] and disease-specific PROs,
such as heart failure [13] and shoulder disorders [14].
Reviews have been published which identify [15],
classify [16–20] or evaluate [8, 21, 22] PRO measures for
prostate cancer patients. However, none of these reviews
used a validated tool for the evaluation. The focus of the
latter three evaluative reviews differed a lot: from generic,
cancer- and prostate cancer-specific PRO instruments [21,
22] to symptom measures [8]. The number of instruments
evaluated varied accordingly from 16 [22] to 29 [8]. Our
study focus was set on instruments measuring the impact of
localized prostate cancer and treatment side effects on
patients’ HRQL, and not just measuring the frequency of
symptoms. The aim of our study was to obtain a systematic
and standardized EMPRO evaluation of the evidence
available on development process, metric properties and
administration issues of prostate cancer-specific HRQL
instruments that are currently applicable in patients with
early-stage disease.
Methods
Systematic review
We identified the prostate cancer-specific HRQL instru-
ments by reviewing the Patient-Reported Outcomes and
Quality of Life Instruments Database (PROQOLID) [23]
and the websites of two cancer research groups: European
Organization for Research and Treatment of Cancer (EO-
RTC)1 and Functional Assessment of Cancer Therapy
Group (FACT).2 We also examined topic-related review
articles [8, 15–22] and their bibliographic reference lists.
We included prostate cancer-specific HRQL instruments
that were applicable to patients with localized disease. We
excluded instruments that are domain- or treatment-spe-
cific, such as the Sexual Health Inventory for Men instru-
ment [24], or the Prostatectomy Therapy Survey Instrument
[25].
Once the instruments were identified (five through
PROQOLID, EORTC and FACT; and three through review
articles in PubMed), we carried out systematic searches for
1 http://groups.eortc.be/qol/eortc-modules.
2 http://www.facit.org/FACITOrg/Questionnaires.
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each instrument in the PubMed database (September 2013)
in order to obtain all the available published evidence. The
search strategy combined the keywords ‘‘urologic cancer’’
or ‘‘prostate cancer’’ and ‘‘quality of life’’ and the name of
the instrument (full name and abbreviation), both as MeSH
terms and free-text entries (see Online Appendix 1). Arti-
cles were eligible for inclusion if they contained informa-
tion regarding the development process of the instrument,
its metric properties and administration issues. We only
considered original research articles published in English,
Spanish, French or German.
In a two-step process, abstracts and full-text articles
were independently reviewed by two investigators (S.S.
and Virginia Becerra). A third investigator (M.F.) mediated
and resolved discrepancies in each step. We then manually
examined the bibliographic reference lists of the articles
selected for full review.
Evaluating Measures of Patient-Reported Outcomes
(EMPRO)
The EMPRO [11] was designed to measure the quality of
PRO instruments. It assesses quality as an overall concept,
which is based on eight attributes (39 items) covering:
‘‘conceptual and measurement model’’ (concepts and
population intended to assess); ‘‘reliability’’ (to which
degree an instrument is free of random error); ‘‘validity’’
(to which degree an instrument measures what it intends);
‘‘responsiveness’’ (ability to detect change over time);
‘‘interpretability’’ (assignment of meanings to instruments’
scores); ‘‘burden’’ (time, effort and other demands for
administration and response); ‘‘alternative modes of
administration’’ (i.e., self- or interviewer-administered,
telephone or computer-assisted interview); and ‘‘cross-
cultural and linguistic adaptations’’ (equivalence across
translated versions). For instruments which had some
country versions available (e.g., Canadian, Dutch, Italian,
Japanese and Spanish [26–30] University of California Los
Angeles-Prostate Cancer Index (UCLA-PCI) versions),
their studies were considered in the EMPRO evaluation.
Nevertheless, the ‘‘cross-cultural and linguistic adaptation’’
attribute was not completed because the separate evalua-
tion of every version was beyond the scope of this study.
All EMPRO attributes and items are accompanied by a
short description to facilitate understanding the intended
meaning and to guarantee a standardized application during
the evaluation process. The item content for each attribute is
summarized in the table of EMPRO results. Agreement with
each item can be answered on a four-point Likert’s scale,
from 4 (strongly agree) to 1 (strongly disagree). The ‘‘no
information’’ box can be checked in case of insufficient
information. Five items allow replying with ‘‘not applica-
ble.’’ It is recommended to provide detailed comments to
justify each EMPRO rating. These comments aid in the
interpretation of the EMPRO scores.
Standardized EMPRO evaluation
Each prostate cancer-specific instrument was evaluated by
two different experts using the EMPRO tool. Experts were
identified and invited because of their expertise and expe-
rience in PRO measurement: Eight were senior researchers
who belonged to the EMPRO tool development working
group, and the other eight were junior researchers who had
previously been certified as EMPRO experts after partici-
pating in a training course and successfully completing a
supervised evaluation. The review pairs were composed of
one senior and one junior researcher. In order to minimize
the potential bias, experts were not authors nor had been
involved in the development or adaptation process of their
assigned instrument.
The EMPRO evaluation process consisted of two con-
secutive rounds. In the first round, every expert indepen-
dently evaluated his or her assigned instrument by
reviewing the full-text articles identified through the sys-
tematic review process and by applying the EMPRO tool
[11]. In the second round, each expert was provided with
the rating results of the other expert who had this instru-
ment assigned. In case of discrepancies, first, they were
invited to resolve them through consensus, and second, if
necessary, they were solved by a third reviewer.
Statistical analysis
Attribute-specific scores and an overall score were calcu-
lated. Detailed information and algorithms to obtain EM-
PRO scores are available online.3 First, the mean of the
applicable items was calculated for each attribute (when at
least 50 % of them were rated); and second, this raw mean
was linearly transformed into a range of 0 (worst possible
score)–100 (best possible score). Items for which the
response option ‘‘no information’’ had been selected were
assigned a score of 1 (lowest possible score). Separate
subscores for the ‘‘reliability’’ and ‘‘burden’’ attributes
were calculated as they are composed of two components
each: ‘‘internal consistency’’ and ‘‘reproducibility’’ for
reliability, as well as ‘‘respondent’’ and ‘‘administrative’’
for burden. For reliability, the highest subscore for the two
components was then chosen to represent the attribute.
Besides the attribute-specific scores, an overall score
was computed by calculating the mean of the five metric-
related attributes: ‘‘conceptual and measurement model,’’
‘‘reliability,’’ ‘‘validity,’’ ‘‘responsiveness to change’’ and
3 http://www.bibliopro.org/sobre_empro/index.html.
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‘‘interpretability.’’ The overall score was only calculated
when at least three of these five attributes had a score.
EMPRO scores were considered reasonably acceptable if
they reached at least 50 points (out of the 100 maximum
theoretical points). This threshold was chosen based on the
global recommendations made by the reviewers in the first
two EMPRO studies [11, 13]. The receiver operating
characteristic (ROC) curve was calculated to evaluate the
agreement between EMPRO attribute scores and the
reviewers’ global recommendations. The area under the
ROC curve was of 0.87 and the suggested cutoff was 51
(data not shown but available upon request).
Results
Characteristics of instruments
We identified eight HRQL instruments applicable to
patients with early-stage prostate cancer, which were
developed between 1997 and 2008 (Table 1). Four instru-
ments were designed for all tumor stages (Estudio sobre la
Calidad de Vida en el Ca´ncer de Pro´stata—ESCAP-CDV
[31], EORTC QLQ-PR25 [32], FACT-P [33], and Patient-
Oriented Prostate Utility Scale—PORPUS [34]) and the
other four were developed specifically for patients at early-
stage disease (Expanded Prostate Cancer Index Compos-
ite—EPIC [35], Prostate Cancer Quality of Life Instru-
ment—PC-QoL [36], Prostate Cancer Symptom Indices—
PCSI [37] and UCLA-PCI [38]). The EORTC QLQ-PR25
[32] and FACT-P [33] are tumor location-specific modules
and were developed to complement the corresponding
cancer-specific core questionnaire that measures general
well-being (EORTC QLQ-C30 and FACT-General,
respectively). The ESCAP-CDV [31] is a Spanish instru-
ment which covers eight dimensions of general health and
one prostate cancer-specific module. The PORPUS [34] is
a unidimensional utility instrument composed by five
general health and five prostate cancer-specific questions.
Most of the instruments differentiate among bowel, sexual
and urinary domains. EPIC [35] was developed from the
UCLA-PCI [38] by supplementing it with items focusing
on urinary irritative and obstructive voiding symptoms, as
well as a hormonal domain. EORTC-PR25 and EPIC are
the only instruments that consider the whole symptom
spectrum (urinary, bowel, sexual and hormonal) in their
content.
Retrieved information
The number of articles initially retrieved from the sys-
tematic literature search varied a lot, ranging from 323
(UCLA-PCI) to only two (ESCAP-CDV). The results of
the systematic review process are described in Table 2.
Most of the articles were excluded because they were not
related to the instrument or did not provide any information
on development process, metric properties or administra-
tion issues. The final number of articles included in the
EMPRO evaluation varied from 16 (UCLA-PCI) to two
(ESCAP-CDV) (Table 1). The bibliographic references of
the included studies are shown in the Online Appendix 2.
Results of the EMPRO ratings
Detailed EMPRO results of the standardized evaluation are
presented in Table 3 and summarized in figure 1. Con-
sensus between the two experts of an instrument was
achieved in almost all cases, and the third expert was only
needed to solve discrepancies for one instrument. The
overall score, which summarizes the five attribute-specific
scores described above, ranged from 83.1 (EPIC) to 21.1
(ESCAP-CDV). In the ‘‘conceptual and measurement
model’’ attribute, instruments scored from 90.5 (EPIC,
UCLA-PCI) to 42.9 (ESCAP-CDV, FACT-P), with six out
of eight instruments presenting scores higher than 50.
‘‘Reliability’’ scores ranged from 75 (PC-QoL) to 25
(FACT-P), and only three instruments scored above the
threshold of 50. ‘‘Validity’’ scores ranged from 100
(PORPUS) to 25.0, with only one instrument below 50
(ESCAP-CDV). In ‘‘responsiveness,’’ instruments scored
from 100 (PC-QoL) to 33.3 (EORTC-PR25), and six out of
eight instruments scored higher than 50. ‘‘Interpretability’’
scores were highest for FACT-P (88.9), followed by EPIC,
PORPUS and UCLA-PCI (each 77.8), though no infor-
mation was found for three instruments. UCLA-PCI and
PC-QOL presented the lowest respondent burden (66.7 and
55.6 points, respectively) and, together with EPIC, also the
lowest administrative burden (ranging from 91.7 to 75
points).
EPIC and UCLA-PCI provide alternative forms of
administration, as well as short forms whose evaluation is
shown in Table 4. Apart from the traditional paper mode,
there is a web administration form for UCLA-PCI [39] and
a telephone administration with interactive voice response
for EPIC [40]. In both cases, the EMPRO score reached 50
points because the alternative administration method was
compared extensively with the original, but without
assessing the whole range of metric properties. EPIC short
forms were well rated (70 points), as good metric proper-
ties were demonstrated for both EPIC-26 and EPIC-Clini-
cal Practice, as well as their comparability with scores of
the original instrument. UCLA-PCI short form was rated
low because only internal consistency reliability was
estimated.
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Discussion
In this study, we assessed the performance of patient self-
reported HRQL instruments applicable for early-stage
prostate cancer disease. Information regarding develop-
ment process, metric properties, and administrative issues
was obtained in systematic reviews of the literature and
was evaluated by experts using a standardized tool. Of the
eight instruments, the best rate according to EMPRO
standard criteria was found for EPIC. Results obtained by
UCLA-PCI, PORPUS and PC-QoL also support good
performance, and therefore, their use should be recom-
mended. FACT-P and PCSI scored slightly above the
threshold of acceptable results, while ESCAP-CDV is far
from this minimum quality criterion.
EPIC and UCLA-PCI
The EPIC and UCLA-PCI scored the highest in the overall
EMPRO assessment. In our study, both instruments were
the best in ‘‘concept and measurement model,’’ and
obtained very high ‘‘validity,’’ ‘‘responsiveness,’’ and
‘‘interpretability’’ results, where they were placed at second
position. Despite these good results of UCLA-PCI, we
recommend EPIC (its upgrade) not only due to its good
reliability, but also because it incorporates a hormonal
domain and urinary subscales for incontinence and irrita-
tive–obstructive symptoms (while UCLA-PCI’s urinary
domain mainly queries incontinence). Both questionnaires
have developed brief versions to minimize administration
burden. The EPIC-26 [41] shortened to 10 min the time
required to complete, and the EPIC for Clinical Practice
[42] with 16 items was designed to be administered and
scored directly during the clinical visit. The short UCLA-
PCI [43] contains 14 of the original 20 items.
PORPUS
PORPUS obtained the third best rating in the overall
summary score. It is the only prostate cancer-specific
instrument combining econometric and psychometric
methods. As a result, it can be used as a preference-based
health index obtaining utilities (PORPUS-U) for economic
evaluation or as a short descriptive HRQL profile (POR-
PUS-P) [34]. In our metric quality evaluation, it was at the
top for ‘‘validity’’ (maximum score), and it ranked second,
equal to EPIC and UCLA-PCI, for ‘‘responsiveness’’ and
‘‘interpretability.’’ However, it just passed the requirements
of ‘‘conceptual and measurement model’’ as experts high-
lighted the need to clarify the different elicitation methods
to obtain utilities with PORPUS-U: direct methods with
standard gamble or rating scale (PORPUS-USG and POR-
PUS-URS), and an indirect method with standard gambleT
a
b
le
2
R
es
u
lt
s
o
f
th
e
sy
st
em
at
ic
li
te
ra
tu
re
re
v
ie
w
.
N
u
m
b
er
o
f
m
an
u
sc
ri
p
ts
id
en
ti
fi
ed
,
ex
cl
u
d
ed
an
d
u
se
d
in
th
e
E
M
P
R
O
ev
al
u
at
io
n
In
st
ru
m
en
t:
ab
b
re
v
ia
ti
o
n
an
d
fu
ll
n
am
e
T
o
ta
l
m
an
u
sc
ri
p
ts
id
en
ti
fi
ed
M
an
u
sc
ri
p
ts
ex
cl
u
d
ed
M
an
u
sc
ri
p
ts
w
it
h
m
et
ri
c
in
fo
rm
at
io
n
(c
o
u
n
tr
y
-s
p
ec
ifi
c)
W
it
h
o
u
t
in
st
ru
m
en
t
in
fo
rm
at
io
n
W
it
h
o
u
t
m
et
ri
c
in
fo
rm
at
io
n
O
th
er
la
n
g
u
ag
e
T
o
ta
l
ex
cl
u
d
ed
E
S
C
A
P
-C
D
V
2
–
–
–
0
2
E
O
R
T
C
Q
L
Q
-P
R
2
5
2
3
6
1
8
1
5
1
–
2
3
2
5
(3
)
E
P
IC
2
3
6
7
0
1
5
1
2
2
2
3
1
3
(4
)
F
A
C
T
-P
1
8
2
1
0
9
5
9
2
1
7
0
1
2
(3
)
P
C
-Q
o
L
1
4
5
1
3
2
1
0
–
1
4
2
3
P
C
S
I
2
7
1
5
7
–
2
2
5
P
O
R
P
U
S
1
2
2
6
–
8
5
U
C
L
A
-P
C
I
3
2
3
9
1
2
1
6
1
3
0
7
1
6
(5
)
In
st
ru
m
en
ts
:
E
S
C
A
P
-C
D
V
E
st
u
d
io
so
b
re
la
C
al
id
ad
d
e
V
id
a
en
el
C
a´n
ce
r
d
e
P
ro´
st
at
a,
E
O
R
T
C
Q
L
Q
-P
R
2
5
E
u
ro
p
ea
n
O
rg
an
iz
at
io
n
fo
r
R
es
ea
rc
h
an
d
T
re
at
m
en
t
in
C
an
ce
r,
Q
u
al
it
y
o
f
L
if
e
G
ro
u
p
-
P
ro
st
at
e
C
an
ce
r
M
o
d
u
le
,
E
P
IC
E
x
p
an
d
ed
P
ro
st
at
e
C
an
ce
r
In
d
ex
C
o
m
p
o
si
te
,
F
A
C
T
-P
F
u
n
ct
io
n
al
A
ss
es
sm
en
t
o
f
C
an
ce
r
T
h
er
ap
y
-P
ro
st
at
e
C
an
ce
r
M
o
d
u
le
,
P
C
-Q
o
L
P
ro
st
at
e
C
an
ce
r
Q
u
al
it
y
o
f
L
if
e
In
st
ru
m
en
t,
P
C
S
I
P
ro
st
at
e
C
an
ce
r
S
y
m
p
to
m
In
d
ic
es
,
P
O
R
P
U
S
P
at
ie
n
t-
O
ri
en
te
d
P
ro
st
at
e
U
ti
li
ty
S
ca
le
,
U
C
L
A
-P
C
I
U
n
iv
er
si
ty
o
f
C
al
if
o
rn
ia
L
o
s
A
n
g
el
es
-P
ro
st
at
e
C
an
ce
r
In
d
ex
Qual Life Res (2014) 23:2169–2181 2175
123
Table 3 Ratings of each EMPRO item and attribute for every prostate cancer-specific quality of life instrument identified
Attributes ESCAP-CDV EORTC PR25 EPIC FACT-P PC-QoL PCSI PORPUS UCLA-PCI
Concept and measurement model 42.9 52.4 90.5 42.9 57.1 66.7 52.4 90.5
1. Concept of measurement stated ???? ???? ???? ???? ???? ???? ???? ????
2. Obtaining and combining items
described
?? ?? ???? ?? ??? ???? ???? ????
3. Rationality for dimensionality and
scales
?? ?? ???? ? ??? ???? ?? ????
4. Involvement of target population ?? ??? ???? ??? ???? ??? ???? ????
5. Scale variability described and
adequate
?? ???? ??? ?? ??? ?? ?? ????
6. Level of measurement described ?? ? ??? ? – ?? ? ??
7. Procedures for deriving scores ?? ?? ???? ??? ? ?? ? ????
Reliability—total score 37.5 62.5 66.7 25.0 75 37.5 33.3 37.5
Reliability: internal consistency 37.5 62.5 62.5 25.0 75 37.5 37.5
8. Data collection methods
described
??? ???? ???? ?? ???? ??? – ??
9. Cronbach’s alpha adequate ?? ??? ??? ?? ???? ?? – ???
10. IRT estimates provided – – – – – – – –
11. Testing in different populations n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a.
Reliability: reproducibility 33.3 66.7 0 50 16.7 33.3 33.3
12. Data collection methods
described
?? – ??? ? ???? ?? ??? ???
13. Test–retest and time interval
adequate
?? – ???? ? ??? ?? ?? ??
14. Reproducibility coefficients
adequate
??? – ???? ? ?? – ?? ??
15. IRT estimates provided – ??? – – – – – –
Validity 25.0 50 91.7 58.3 91.7 50 100 91.7
16. Content validity adequate ?? ? ??? ??? ??? ?? ???? ????
17. Construct/criterion validity
adequate
?? ???? ???? ??? ???? ?? ???? ???
18. Sample composition described ? ??? ???? ?? ???? ??? ???? ????
19. Prior hypothesis stated ?? ?? ???? ??? ???? ??? ???? ????
20. Rational for criterion validity n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a.
21. Tested in different populations n.a. n.a. n.a. n.a. n.a. n.a. n.a. n.a.
Responsiveness 33.3 88.9 55.6 100 55.6 88.9 88.9
22. Adequacy of methods – ??? ???? ??? ???? ??? ??? ???
23. Description of estimated
magnitude of change
– ?? ???? ??? ???? ??? ???? ????
24. Comparison of stable and
unstable groups
– – ??? ?? ???? ?? ???? ????
Interpretability 77.8 88.9 55.6 77.8 77.8
25. Rational of external criteria – – ??? ??? – ??? ???? ???
26. Description of interpretation
strategies
– – ??? ???? – ??? ?? ???
27. How data should be reported
stated
– – ???? ???? – ?? ???? ????
OVERALL SCORE 21.1 39.7 83.1 54.1 64.8 53.1 70.5 77.3
Burden
Burden: respondent 22.2 33.3 44.4 22.2 55.6 0 66.7
28. Skills and time needed ?? ?? ?? ?? ???? – ? ????
29. Impact on respondents ?? ??? ???? ?? ??? – ? ????
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(PORPUS-UI) [44, 45]. EMPRO scores for reliability were
low because the intraclass correlation coefficient of POR-
PUS-U was 0.66 [44] (lower than 0.7), and the test–retest
design was insufficiently described. The PORPUS is the
only prostate cancer-specific instrument for which general
population-based norms exist to facilitate its score inter-
pretation [46].
PC-QoL and PCSI
The PC-QoL obtained the fourth best rating in the overall
summary score. Despite being at the top on ‘‘reliability’’
and ‘‘responsiveness’’ and the second on ‘‘validity,’’ it is
penalized for lacking information on ‘‘interpretability.’’
The first version [36] consisted of 52 items summarized in
10 domains. Befort et al. [47] revised the instrument and
made it a 46-item questionnaire with eight scales that also
provides adequate metric properties. The PCSI ranked sixth
on the overall score and met the minimum quality criteria
for all the attributes except ‘‘reliability.’’ The authors
proposed the use of internal anchors employing the
instrument’s distress or bother items to establish cutoff
points (good, intermediate or poor function) [48]. This
strategy was later deployed for the interpretation of other
instruments such as EPIC and UCLA-PCI [49, 50]. It is the
only instrument that considers patients’ cancer worry.
FACT-P and EORTC QLQ-PR25
Overall performance of FACT-P was acceptable, while
EORTC QLQ-PR25 did not reach the threshold of 50
points. FACT-P was at the top for ‘‘interpretability,’’ with a
2–3 point clinically meaningful change estimation using
anchor-based and distribution-based methods [51], but it
presented low scores on reliability mainly because of poor
rates on study methods and internal consistency results
(Cronbach’s a below 0.7 [33]). On the other hand, since the
clinically meaningful change was estimated among patients
suffering from metastatic hormone-refractory prostate
cancer, its applicability for localized disease merits further
research. EORTC QLQ-PR25 is strongly penalized due to
the lack of information regarding its interpretability and for
providing inadequate results on responsiveness. Experts
highlighted that the coefficient used to estimate the mag-
nitude of change was insufficiently described [32], and no
comparison with a stable group had been performed.
However, it should be taken into account that EORTC
QLQ-PR25 was the newest instrument, and to date, it has
few publications in biomedical literature databases. EO-
RTC and FACT developed their modules simultaneously in
several languages, which represent an advantage to con-
sider when choosing an instrument for multicentric inter-
national studies requiring different country versions.
Comparison with other evaluative reviews
Our work has both similarities and differences when com-
pared to the three evaluative reviews [8, 21, 22]. Consis-
tently with our findings, EPIC and UCLA-PCI are always
among the most highly recommended [8, 21, 22]; PC-QoL
[8, 21] and PORPUS [21] also obtained high ratings in other
reviews; and the PCSI also met the minimum standard
criteria to be recommended in the only other review where
it was included [8]. On the other hand, the only major dif-
ference detected with respect to previous reviews concerns
the recommendation of FACT-P module. Rnic et al. [8],
similarly to our study, assigned it an unfavorable reliability
evaluation according to the Cronbach’s a coefficient of 0.65
and 0.69 reported by Esper et al. [33]. Yet Hamoen et al.
[21] and the Oxford group [22] recommended the FACT-P:
the first article assigned full points to internal consistency
[21], and the second one rated it with ‘‘some limited evi-
dence in favor’’ [22]. These results suggest a higher exi-
gency on the EMPRO requirements in comparison with
Table 3 continued
Attributes ESCAP-CDV EORTC PR25 EPIC FACT-P PC-QoL PCSI PORPUS UCLA-PCI
30. Not suitable circumstances – – – – – – – –
Burden: administrative 91.7 75 8.3 91.7
31. Resources required – – ???? – ???? – ? ????
32. Time required – – ???? – ???? – ?? ????
33. Training and expertise needed – – ??? – ???? – – ????
34. Burden of score calculation ?? ? ???? ? – – – ???
Explanation: ???? 4 (strongly agree), ??? 3, ?? 2, ? 1 (strongly disagree), – no information, n.a. not applicable. The higher the agreement
the better the rating
Instruments: ESCAP-CDV Estudio sobre la Calidad de Vida en el Ca´ncer de Pro´stata, EORTC QLQ-PR25 European Organization for Research
and Treatment in Cancer, Quality of Life Group-Prostate Cancer Module, EPIC Expanded Prostate Cancer Index Composite, FACT-P Functional
Assessment of Cancer Therapy-Prostate Cancer Module, PC-QoL Prostate Cancer Quality of Life Instrument, PCSI Prostate Cancer Symptom
Indices, PORPUS Patient-Oriented Prostate Utility Scale, UCLA-PCI University of California Los Angeles-Prostate Cancer Index
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other evaluations and differences on the evaluation criteria
applied. Rnic et al. [8] examined only 4 criteria (compre-
hensiveness, subjectivity of experience, internal consis-
tency and extent of validation), while the attributes
considered in the other two evaluations [21, 22] are similar
to the EMPRO content. However, the only tool that gen-
erates attribute scores which are based on multiple items
(ranging from 2 to 7) is EMPRO, thus resulting in a more
exhaustive and comprehensive evaluation.
Study limitations
Our findings should be interpreted taking into account the
study limitations. Firstly, the basis of our results is the
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Fig. 1 Overall ranking of instruments and their attribute-specific
EMPRO scores. EMPRO scores ranged 0–100 (worst to best).
Instruments: ESCAP-CDV Estudio sobre la Calidad de Vida en el
Ca´ncer de Pro´stata, EORTC QLQ-PR25 European Organization for
Research and Treatment in Cancer, Quality of Life Group-Prostate
Cancer Module, EPIC Expanded Prostate Cancer Index Composite,
FACT-P Functional Assessment of Cancer Therapy-Prostate Cancer
Module, PC-QoL Prostate Cancer Quality of Life Instrument, PCSI
Prostate Cancer Symptom Indices, PORPUS Patient-Oriented Pros-
tate Utility Scale, UCLA-PCI University of California Los Angeles-
Prostate Cancer Index
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information retrieved in systematic literature reviews
conducted only in the PubMed database. Although it is the
leading database in health sciences, we may have failed to
identify all the published articles with information on
development process, metric properties or administration
issues. However, the sensitive search strategy specifically
designed for each instrument, the additional hand search of
references, as well as the double independent review pro-
cess followed, may have minimized this problem. Sec-
ondly, the EMPRO evaluation is based on the quantity and
quality of published evidence. A lack of evidence for a few
EMPRO items or attributes penalizes the EMPRO scores,
because the scoring algorithm counts any missing infor-
mation as the worst possible rating. Nevertheless, to avoid
a strong penalization, the EMPRO score is not calculated if
more than half of the information is missing. Not pre-
senting proposals for interpretability penalized the overall
score for some of the instruments. Therefore, developing
strategies to facilitate the interpretation of scores (such as
estimating the minimal important difference by using
anchor-based or distribution-based strategies, or providing
reference values) is recommended. These interpretation
proposals may help to extend these PRO measures beyond
the research setting. Thirdly, EMPRO ratings may be
biased by the individual expertise of the evaluators,
although the double and independent review conducted, as
well as a comprehensive description of each item, may
have attenuated this concern. Fourthly, studies on metric
properties from different country versions (EORTC PR25,
EPIC, FACT-P and UCLA-PCI) were considered in our
EMPRO evaluation. Although these country versions can
add noise in one sense, they also provide valuable infor-
mation about the generalizability of the psychometric data
to these measures. Fifthly, although clinical trials can
provide evidence on some metric properties such as
validity, sensitivity to change or interpretability, none was
included in our study. These trials were considered inap-
propriate because they were not specifically designed for
the assessment of metric properties, nor included it as a
secondary objective. For example, neither differences nor a
lack of differences in PRO scores between trial arms could
be interpreted as the instrument’s responsiveness if there is
no clear underlying hypothesis about change. Finally, as
the standard error of measurement was not considered
separately in EMPRO, the only information on the preci-
sion of the inferences at the individual level is based on the
reliability of the instrument. Therefore, we cannot address
the usefulness of these eight instruments at the individual
patient’s level.
Conclusions
In conclusion, the evidence would currently support a
preference for the use of EPIC, PORPUS and PC-QoL.
Choosing among them will mainly depend on particular
study requirements. For longitudinal studies or clinical
trials, where responsiveness and reproducibility are the
maximum priority, PC-QoL or EPIC would be recom-
mended. For economic evaluations, PORPUS would be
chosen as it allows cost-utility analysis. The brief versions
might be preferred to minimize administration burden:
EPIC short [41], EPIC-Clinical Practice [42] or short
UCLA-PCI [43]. Our results facilitate the decision process
regarding the correct instrument selection and its use and
interpretation for a certain study purpose or setting.
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